



## **Final Appraisal Recommendation**

### **Sodium valproate (Episenta®)**

**Limited submission by:  
Beacon Pharmaceuticals Ltd**

**Advice No: 2111 – December 2011**

### **Recommendation of AWMSG**

**Sodium valproate (Episenta®) is recommended as an option for use within NHS Wales for the treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate (Episenta®) for acute mania.**

**AWMSG is of the opinion that sodium valproate (Episenta®) may be suitable for shared care within NHS Wales.**

#### **Additional notes:**

Sodium valproate (Episenta®) met the following criteria for eligibility for a limited submission:

- New formulation with a pro-rata or lower cost per treatment.
- A minor licence extension.
- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: